Skip to content Skip to footer
Subscribe Now
NEWS

Deciphera Pharmaceuticals Reports the EC’s Approval of Romvimza for Symptomatic Tenosynovial Giant Cell Tumor (TGCT)

Shots: The EC has approved Romvimza (vimseltinib) to treat symptomatic TGCT with physical function deterioration in adults for which surgery may lead to functional impairment or severe morbidity Approval was based on P-I/II trial as well as P-III (MOTION) trial, which evaluated Romvimza vs PBO in surgery-ineligible pts without prior anti-CSF1/CSF1R therapy (prior imatinib/nilotinib allowed)…
September 18, 2025

Read more

NEWS

Deciphera Pharmaceuticals Reports the CHMP’s Positive Opinion of Romvimza for Symptomatic Tenosynovial Giant Cell Tumor (TGCT)

Shots: The CHMP has recommended Romvimza (vimseltinib) to treat symptomatic TGCT with physical function deterioration in adults for which surgery may lead to functional impairment or severe morbidity; EC’s decision is expected in Q3'25 Opinion was based on P-I/II trial as well as P-III (MOTION) trial, which evaluated Romvimza vs PBO in surgery-ineligible pts without…
July 29, 2025

Read more

Viewpoints_Mathew L. Sherman
VIEWPOINTS

PharmaShots Interview: Deciphera’s Mathew L. Sherman Shares Insight on Data of QINLOCK and DCC-3014 Presented at CTOS 2020

In an interview with PharmaShots, Matthew L. Sherman, M.D., Executive Vice President and Chief Medical Officer of Deciphera shed light on encouraging preliminary results from the ongoing P-I/II study of DCC-3014 in TGCT patients and also presented the data of QINLOCK at CTOS 2020 Shots: Deciphera presented encouraging preliminary results from the ongoing Phase 1/2 study of DCC-3014 in tenosynovial giant cell tumor…
February 17, 2021

Read more